Clopimozide

Clopimozide
Clopimozide
Systematic (IUPAC) name
3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidyl]-6-chloro-1H-benzimidazol-2-one
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 53179-12-7
ATC code  ?
PubChem CID 65449
ChemSpider 58909
UNII 7C6TA32SD2 YesY
KEGG D02649
Chemical data
Formula C28H28ClF2N3O
Mol. mass 495.99 g/mol
SMILES eMolecules & PubChem

Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class.[1][2] It is very potent and has an extremely long duration of action, lasting at least one week with a single dose.[3][4][5] It was developed by Janssen Pharmaceutica but was never marketed.

See also

References

  1. ^ De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica 59 (5): 561–74. PMID 37697. 
  2. ^ Knapen J, Bollen J, Brugmanns J, Rombaut N (1976). "[Treatment of chronic psychoses with oral clopimozide]" (in French). Acta Psychiatrica Belgica 76 (4): 644–57. PMID 798469. 
  3. ^ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A (August 1975). "Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series". Arzneimittel-Forschung 25 (8): 1287–94. PMID 1242360. 
  4. ^ Floru L, Tegeler J (1978). "Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764)". Arzneimittel-Forschung 28 (2): 341–4. PMID 25071. 
  5. ^ Bobon J, Parent M, Toussaint C, Pinchard A (1976). "[Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)]" (in French). Acta Psychiatrica Belgica 76 (1): 138–43. PMID 970182.